LATEST NEWS
December 13, 2023 | Company Announcements
New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic November 30, 2023 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant ExerciseNovember 16, 2023 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Nine Months of 2023October 25, 2023 | Company Announcements
Bavarian Nordic’s Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at RiskSeptember 13, 2023 | Press Releases
Bavarian Nordic Awarded Another Contract to Supply Smallpox Vaccines for EU Strategic ReserveAugust 31, 2023 | Company Announcements
Bavarian Nordic Provides Update on COVID-19 Booster Vaccine ProgramAugust 23, 2023 | Company Announcements
Bavarian Nordic Announces First Half 2023 ResultsAugust 06, 2023 | Company Announcements
Bavarian Nordic Reports Positive Phase 3 Topline Results for Chikungunya Virus Vaccine in Adults and Adolescents August 03, 2023 | Company Announcements
Bavarian Nordic Receives USD 120 Million Contract for the Manufacturing of Smallpox and Mpox Vaccine from the U.S. GovernmentJuly 22, 2023 | Company Announcements
Bavarian Nordic Provides Update on RSV Vaccine Program